Abstract:In psychiatric disorders, common and rare genetic variants cause widespread dysfunction of cells and their interactions, especially in the prefrontal cortex, giving rise to psychiatric symptoms. To better understand these processes, we traced the effects of common and rare genetics, and cumulative disease risk scores, to their molecular footprints in human cortical single-cell types. We demonstrated that examining gene expression at single-exon resolution is crucial for understanding the cortical dysregulation associated with diagnosis and genetic risk derived from common variants. We then used disease risk scores to identify a core set of genes that serve as a footprint of common and rare variants in the cortex. Pathways enriched in these genes included dopamine regulation, circadian entrainment, and hormone regulation. Single-nuclei-RNA-sequencing pinpointed these enriched genes to excitatory cortical neurons. This study highlights the importance of studying sub-gene-level genetic architecture to classify psychiatric disorders based on biology rather than symptomatology, to identify novel targets for treatment development. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233860/pdf/jove-20-914.pdf> ### Funding Statement The Victorian Brain Bank tissue collection was supported by the National Health and Medical Research Council (NHMRC; Australia; grant number 566967) and the Cooperative Research Centre (CRC) for Mental Health and the Operational Infrastructure Support from the Victorian State Government. The New South Wales Brain Tissue Resource Centre at the University of Sydney was supported by the University of Sydney. Research reported in this publication was supported by the National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number NIAAA012725-15. The content is solely the responsibility of the authors and does not represent the official views of the National Institutes of Health. Dr Knauer-Arloth was supported by the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #28063). Dr Matosin was supported by an Al and Val Rosenstrauss Fellowship from the Rebecca L Cooper Medical Research Foundation and grants from the Brain Behaviour Research Foundation (NARSAD Young Investigator Grant, #26486) and the Rebecca L. Cooper Medical Research Foundation (#PG2020645). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of the Victorian Institute of Forensic Medicine gave ethical approval for this work. Ethics committee/IRB of the Human Ethics Committee of Melbourne Health gave ethical approval for this work. Ethics committee/IRB of the Central Institute of Mental Health Mannheim gave ethical approval for this work. Ethics committee/IRB of the University Hospital Bonn gave ethical approval for this work. Ethics committee/IRB of the Human Research Ethics Committees at the University of Wollongong gave ethical approval for this work. Ethics committee/IRB of the Ludwig-Maximilians-Universitaet Muenchen gave ethical approval for this work. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes Expression data of dataset 1 in the present study are available online at GEO (GSE208338) and the genotypes are available upon reasonable request to the authors. Genes altered by rare coding variants from SCHEMA exome sequencing results in dataset 2 are available online at https://schema.broadinstitute.org/downloads. snRNA-seq data of dataset 3 in the present study are available online at GEO (GSE205642). <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE205642> <https://drive.google.com/drive/folders/1JRyThjCwb7JFE6LdQQiAHwXQZFIO2o0V?usp=sharing> <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE208338> <https://schema.broadinstitute.org/downloads>

Lessons from two series by physicians and caregivers' self‐reported data in DDX3X‐related disorders

Genotype–phenotype correlations and novel molecular insights into the DHX30-associated neurodevelopmental disorders

DDX3X Syndrome Behavioral Manifestations with Particular Emphasis on Psycho-Pathological Symptoms-A Review

Multiple molecular diagnoses in the field of intellectual disability and congenital anomalies: 3.5% of all positive cases

Clinico-biological refinement of BCL11B-related disorder and identification of an episignature: A series of 20 unreported individuals

Variant-risk-exon interplay impacts circadian rhythm and dopamine signaling pathway in severe psychiatric disorders

The clinical and molecular spectrum of the KDM6B-related neurodevelopmental disorder

Pathogenic DDX3X Mutations Impair RNA Metabolism and Neurogenesis during Fetal Cortical Development

Assessing the Landscape of STXBP1-related Disorders in 534 Individuals

Expectations, needs and mid-term outcomes in people accessing to secondary findings from ES: 1st French mixed study (FIND Study)

Social and emotional characteristics of girls and young women with DDX3X-associated intellectual disability: a descriptive and comparative study

Monoallelic de novo variants in DDX17 cause a neurodevelopmental disorder

Mutations in DDX3X Are a Common Cause of Unexplained Intellectual Disability with Gender-Specific Effects on Wnt Signaling

Large-scale targeted sequencing identifies risk genes for neurodevelopmental disorders

The protean presentations of XK disease (McLeod syndrome): a case series with new observations and updates on previously reported families

Epilepsy Course and Developmental Trajectories in STXBP1-DEE

Genome-Wide Association Study Meta-Analysis of 9619 Cases With Tic Disorders

Expanding the genetic and clinical spectrum of Tatton-Brown-Rahman syndrome in a series of 24 French patients

Neuropsychiatric symptoms in genetic frontotemporal dementia: developing a new module for Clinical Rating Scales

Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties: Insights from Clinical Practice

Associations Between Attention-Deficit/Hyperactivity Disorder and Various Eating Disorders: A Swedish Nationwide Population Study Using Multiple Genetically Informative Approaches.